

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 October 2021 (14.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/207599 A9

(51) International Patent Classification:		63/008,515	10 April 2020 (10.04.2020)	US
	<i>C07K 14/005</i> (2006.01)	<i>A61P 31/14</i> (2006.01)	19 June 2020 (19.06.2020)	US
	<i>A61K 39/12</i> (2006.01)	<i>A61K 38/00</i> (2006.01)	19 June 2020 (19.06.2020)	US
(21) International Application Number:		63/041,582	19 June 2020 (19.06.2020)	US
		63/041,584	19 June 2020 (19.06.2020)	US
	PCT/US2021/026577	63/048,939	07 July 2020 (07.07.2020)	US
(22) International Filing Date:		63/068,775	21 August 2020 (21.08.2020)	US
	09 April 2021 (09.04.2021)	63/068,805	21 August 2020 (21.08.2020)	US
		63/068,843	21 August 2020 (21.08.2020)	US
(25) Filing Language:	English	63/068,894	21 August 2020 (21.08.2020)	US
(26) Publication Language:	English	63/068,911	21 August 2020 (21.08.2020)	US
(30) Priority Data:				
	63/008,497	10 April 2020 (10.04.2020)	US	
	63/008,503	10 April 2020 (10.04.2020)	US	
	63/008,509	10 April 2020 (10.04.2020)	US	
(71) Applicant: AKSTON BIOSCIENCES CORPORATION [US/US]; 100 Cummings Center, Ste 454C, Beverly, Massachusetts 01915 (US).				

(54) Title: ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE




FIG. 2

(57) **Abstract:** The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (CQVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naive patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

[Continued on next page]

(72) **Inventors:** **ZION, Todd C.**; 72 Nanepashemet Street, Marblehead, Massachusetts 01945 (US). **LANCASTER, Thomas M.**; 166 Larch Row, Wenham, Massachusetts 01984 (US). **SATHIYASEELAN, Thillainayagam**; 184 Concord Avenue, Lexington, Massachusetts 02421 (US). **HUANG, Kexin**; 3405 Branson Drive, San Mateo, California 94403 (US).

(74) **Agent:** **COOK, Crissa A.**; Hovey Williams LLP, 10801 Mastin Blvd., Suite 1000, Overland Park, Kansas 66210 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))

(48) **Date of publication of this corrected version:**
06 January 2022 (06.01.2022)

(15) **Information about Correction:**
see Notice of 06 January 2022 (06.01.2022)